## Yasin Mamatjan

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6610078/publications.pdf

Version: 2024-02-01

430442 301761 1,719 75 18 39 citations h-index g-index papers 76 76 76 2410 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	IDH mutant diffuse and anaplastic astrocytomas have similar age at presentation and little difference in survival: a grading problem for WHO. Acta Neuropathologica, 2015, 129, 867-873.	3.9	272
2	DNA methylation profiling to predict recurrence risk in meningioma: development and validation of a nomogram to optimize clinical management. Neuro-Oncology, 2019, 21, 901-910.	0.6	184
3	A clinically applicable integrative molecular classification of meningiomas. Nature, 2021, 597, 119-125.	13.7	180
4	The genomic landscape of schwannoma. Nature Genetics, 2016, 48, 1339-1348.	9.4	124
5	Advances in multidisciplinary therapy for meningiomas. Neuro-Oncology, 2019, 21, i18-i31.	0.6	102
6	Imaging and diagnostic advances for intracranial meningiomas. Neuro-Oncology, 2019, 21, i44-i61.	0.6	100
7	Molecular and translational advances in meningiomas. Neuro-Oncology, 2019, 21, i4-i17.	0.6	92
8	Therapeutic radiation for childhood cancer drives structural aberrations of NF2 in meningiomas. Nature Communications, 2017, 8, 186.	5.8	76
9	Life after surgical resection of a meningioma: a prospective cross-sectional study evaluating health-related quality of life. Neuro-Oncology, 2019, 21, i32-i43.	0.6	56
10	Evaluation of EIT system performance. Physiological Measurement, 2011, 32, 851-865.	1.2	52
10	Evaluation of EIT system performance. Physiological Measurement, 2011, 32, 851-865.  The central nervous system tumor methylation classifier changes neuro-oncology practice for challenging brain tumor diagnoses and directly impacts patient care. Clinical Epigenetics, 2019, 11, 185.	1.2	51
	The central nervous system tumor methylation classifier changes neuro-oncology practice for		
11	The central nervous system tumor methylation classifier changes neuro-oncology practice for challenging brain tumor diagnoses and directly impacts patient care. Clinical Epigenetics, 2019, 11, 185.  Ketoconazole and Posaconazole Selectively Target HK2-expressing Glioblastoma Cells. Clinical Cancer	1.8	51
11 12	The central nervous system tumor methylation classifier changes neuro-oncology practice for challenging brain tumor diagnoses and directly impacts patient care. Clinical Epigenetics, 2019, 11, 185.  Ketoconazole and Posaconazole Selectively Target HK2-expressing Glioblastoma Cells. Clinical Cancer Research, 2019, 25, 844-855.  Clinical impact of combined epigenetic and molecular analysis of pediatric low-grade gliomas.	1.8 3.2	51
11 12 13	The central nervous system tumor methylation classifier changes neuro-oncology practice for challenging brain tumor diagnoses and directly impacts patient care. Clinical Epigenetics, 2019, 11, 185.  Ketoconazole and Posaconazole Selectively Target HK2-expressing Glioblastoma Cells. Clinical Cancer Research, 2019, 25, 844-855.  Clinical impact of combined epigenetic and molecular analysis of pediatric low-grade gliomas. Neuro-Oncology, 2020, 22, 1474-1483.  Impact of the methylation classifier and ancillary methods on CNS tumor diagnostics.	1.8 3.2 0.6	51 51 39
11 12 13	The central nervous system tumor methylation classifier changes neuro-oncology practice for challenging brain tumor diagnoses and directly impacts patient care. Clinical Epigenetics, 2019, 11, 185.  Ketoconazole and Posaconazole Selectively Target HK2-expressing Glioblastoma Cells. Clinical Cancer Research, 2019, 25, 844-855.  Clinical impact of combined epigenetic and molecular analysis of pediatric low-grade gliomas. Neuro-Oncology, 2020, 22, 1474-1483.  Impact of the methylation classifier and ancillary methods on CNS tumor diagnostics. Neuro-Oncology, 2022, 24, 571-581.	1.8 3.2 0.6	51 51 39 39
11 12 13 14	The central nervous system tumor methylation classifier changes neuro-oncology practice for challenging brain tumor diagnoses and directly impacts patient care. Clinical Epigenetics, 2019, 11, 185.  Ketoconazole and Posaconazole Selectively Target HK2-expressing Glioblastoma Cells. Clinical Cancer Research, 2019, 25, 844-855.  Clinical impact of combined epigenetic and molecular analysis of pediatric low-grade gliomas. Neuro-Oncology, 2020, 22, 1474-1483.  Impact of the methylation classifier and ancillary methods on CNS tumor diagnostics. Neuro-Oncology, 2022, 24, 571-581.  TNFî± secreted by glioma associated macrophages promotes endothelial activation and resistance against anti-angiogenic therapy. Acta Neuropathologica Communications, 2021, 9, 67.  Epigenomic, genomic, and transcriptomic landscape of schwannomatosis. Acta Neuropathologica,	1.8 3.2 0.6 0.6	51 51 39 39 28

#	Article	IF	Citations
19	Integrative analysis of non-small cell lung cancer patient-derived xenografts identifies distinct proteotypes associated with patient outcomes. Nature Communications, 2022, 13, 1811.	5.8	21
20	Programmed death ligand-1 (PD-L1) expression in meningioma; prognostic significance and its association with hypoxia and NFKB2 expression. Scientific Reports, 2020, 10, 14115.	1.6	20
21	An experimental clinical evaluation of EIT imaging with $\hat{a}$ , " <sub>1</sub> data and image norms. Physiological Measurement, 2013, 34, 1027-1039.	1.2	19
22	5-Hydroxymethylcytosine preferentially targets genes upregulated in isocitrate dehydrogenase 1 mutant high-grade glioma. Acta Neuropathologica, 2018, 135, 617-634.	3.9	15
23	Norrin mediates tumor-promoting and -suppressive effects in glioblastoma via Notch and Wnt. Journal of Clinical Investigation, 2020, 130, 3069-3086.	3.9	15
24	Enhancing Impedance Imaging Through Multimodal Tomography. IEEE Transactions on Biomedical Engineering, 2011, 58, 3215-3224.	2.5	14
25	Transcriptome and methylome analysis of CNS germ cell tumor finds its cell-of-origin in embryogenesis and reveals shared similarities with testicular counterparts. Neuro-Oncology, 2022, 24, 1246-1258.	0.6	14
26	Hypoxia Can Induce Migration of Glioblastoma Cells Through a Methylation-Dependent Control of ODZ1 Gene Expression. Frontiers in Oncology, 2019, 9, 1036.	1.3	13
27	Evaluation and Real-Time Monitoring of Data Quality in Electrical Impedance Tomography. IEEE Transactions on Medical Imaging, 2013, 32, 1997-2005.	5.4	10
28	Automated robust test framework for electrical impedance tomography. Physiological Measurement, 2015, 36, 1227-1244.	1.2	10
29	c-Src Phosphorylates and Inhibits the Function of the CIC Tumor Suppressor Protein. Molecular Cancer Research, 2020, 18, 774-786.	1.5	10
30	BRAF V600E mutant oligodendrogliomaâ€ike tumors with chromosomal instability in adolescents and young adults. Brain Pathology, 2020, 30, 515-523.	2.1	8
31	Rare IDH1 variants are common in pediatric hemispheric diffuse astrocytomas and frequently associated with Li-Fraumeni syndrome. Acta Neuropathologica, 2020, 139, 795-797.	3.9	7
32	Paediatric atypical choroid plexus papilloma: is adjuvant therapy necessary?. Journal of Neuro-Oncology, 2021, 155, 63-70.	1.4	6
33	Brain-computer interface speller using hybrid P300 and motor imagery signals. , 2012, , .		5
34	Imaging of hemorrhagic stroke in magnetic induction tomography: An in vitro study. International Journal of Imaging Systems and Technology, 2014, 24, 161-166.	2.7	5
35	A dural-based spindle cell neoplasm characterized by a novel MN1-KMT2A fusion gene. Neuro-Oncology, 2019, 21, 1082-1083.	0.6	3
36	Transcription factor networks of oligodendrogliomas treated with adjuvant radiotherapy or observation inform prognosis. Neuro-Oncology, 2021, 23, 795-802.	0.6	3

#	Article	IF	Citations
37	Experimental/clinical evaluation of EIT image reconstruction with â, " <sub>1</sub> data and image norms. Journal of Physics: Conference Series, 2013, 434, 012078.	0.3	1
38	56 Unique Immune Microenvironment in NF2-Fusion Positive Radiation Induced Meningiomas. Canadian Journal of Neurological Sciences, 2018, 45, S17-S17.	0.3	1
39	TMIC-17. IMMUNE MICROENVIRONMENT OF NF2-ALTERED RADIATION-INDUCED MENINGIOMAS. Neuro-Oncology, 2018, 20, vi259-vi259.	0.6	1
40	71. MGMT PROMOTER METHYLATION IS A PROGNOSTIC BIOMARKER IN EGFR MUTANT LUNG ADENOCARCINOMA WITH BRAIN METASTASES. Neuro-Oncology Advances, 2020, 2, ii15-ii15.	0.4	1
41	Clinical value of methylation testing: a case report of intraventricular schwannomas with associated molecular findings. Neuro-Oncology Advances, 2020, 2, vdaa029.	0.4	1
42	Rapid estimation of object movements in magnetic induction tomography. International Journal of Biomedical Engineering and Technology, 2018, 27, 290.	0.2	1
43	Electrical localization of weakly electric fish using neural networks. Journal of Physics: Conference Series, 2013, 434, 012006.	0.3	O
44	A Novel Method for Monitoring Data Quality in Electrical Impedance Tomography. Journal of Physics: Conference Series, 2013, 434, 012077.	0.3	0
45	EPIG-13ROBUST MGMT METHYLATION DETECTION USING 450k ARRAY IN CIMP-NEGATIVE GBM. Neuro-Oncology, 2015, 17, v89.1-v89.	0.6	O
46	154 Genomic Landscape of Radiation-Induced Meningiomas. Neurosurgery, 2017, 64, 238.	0.6	0
47	Rapid estimation of object movements in magnetic induction tomography. International Journal of Biomedical Engineering and Technology, 2018, 27, 290.	0.2	O
48	46 Integration of multiple platforms to discover idh-mutant glioma subtypes. Canadian Journal of Neurological Sciences, 2018, 45, S14-S15.	0.3	0
49	GENE-26. MOLECULAR CHARACTERIZATION OF BENIGN AND MALIGNANT PERIPHERAL NERVE SHEATH TUMORS THAT OCCUR IN SPORADIC AND SYNDROMIC SETTINGS. Neuro-Oncology, 2018, 20, vi108-vi109.	0.6	O
50	LGG-10. EPIGENETIC/GENETIC/MORPHOLOGIC ANALYSES REVEAL CLINICAL/PROGNOSTIC INSIGHT OF PEDIATRIC LOW GRADE GLIOMAS. Neuro-Oncology, 2018, 20, i106-i106.	0.6	0
51	TMIC-07. HYPOXIC MICROENVIRONMENT CONFERS SPECIFIC ALTERATIONS IN DNA METHYLATION PROFILES IN GLIOBLASTOMA. Neuro-Oncology, 2018, 20, vi257-vi257.	0.6	O
52	PATH-25. SURVIVAL STRATIFICATION OF IDH MUTANT GLIOMA USING METHYLATION AND mRNA ANALYSIS OF HOX GENES. Neuro-Oncology, 2018, 20, vi163-vi164.	0.6	0
53	RTHP-07. TRANSCRIPTION FACTOR NETWORKS OF OLIGODENDROGLIOMAS (IDH-MUTANT AND $1p/19q$ ) Tj ETQq Neuro-Oncology, 2018, 20, vi226-vi226.	1 1 0.7843 0.6	314 rgBT / <mark>○</mark> 0
54	MNGI-12. EXPRESSION OF PROGRAMMED CELL DEATH LIGAND-1 (PD-L1) IN MENINGIOMA: CLINICAL UTILITY FOR PREDICTION OF TUMOR RECURRENCE AND ASSOCIATION WITH HYPOXIC RESPONSE AND NFKB2 ACTIVATION. Neuro-Oncology, 2018, 20, vi150-vi151.	0.6	0

#	Article	IF	CITATIONS
55	GENE-08. SCHWANNOMATOSIS SCHWANNOMAS HARBOR DISTINCT DNA METHYLATION PROFILES. Neuro-Oncology, 2018, 20, vi104-vi104.	0.6	0
56	CBMT-06. LOWER GRADE ISOCITRATE DEHYDROGENASE (IDH) MUTANT GLIOMAS METABOLICALLY MIMICKING GLIOBLASTOMA (GBM) EXPRESS HIGHER R:S 2-HYDROXYGLUTARATE RATIOS RELATIVE TO NON-GBM-MIMICKING IDH MUTANT GLIOMAS. Neuro-Oncology, 2018, 20, vi33-vi33.	0.6	0
57	GENE-05. UPREGULATION OF ODZ1-MEDIATED INVASION IN THE HYPOXIC TUMOR MICROENVIRONMENT IN GLIOBLASTOMA. Neuro-Oncology, 2018, 20, vi103-vi103.	0.6	0
58	40 Prognostic significance of PD-L1 expression in meningioma for tumor recurrence; associated with hypoxia and NFKB2 activation. Canadian Journal of Neurological Sciences, 2018, 45, S8-S8.	0.3	0
59	Integrated Multi-Omics Characterization of Neurofibromatosis Type 1 Related Peripheral Nerve Sheath Tumors Identifies Two Distinct Malignant Peripheral Nerve Sheath Tumors Subtypes with Sonic Hedgehog or WNT Pathway Activation. Neurosurgery, 2019, 66, .	0.6	O
60	BSCI-26. COMPARATIVE METHYLATION PROFILING OF EGFR MUTANT LUNG ADENOCARCINOMA AND PAIRED BRAIN METASTASIS. Neuro-Oncology Advances, 2019, 1, i5-i6.	0.4	0
61	CMET-30. COMPREHENSIVE METHYLOME ANALYSIS OF EGFR-MUTANT PRIMARY LUNG ADENOCARCINOMA AND MATCHED BRAIN METASTASIS. Neuro-Oncology, 2019, 21, vi58-vi58.	0.6	0
62	CMET-32. DNA METHYLATION ALTERATIONS IN LUNG ADENOCARCINOMAS THAT DEVELOP BRAIN METASTASES. Neuro-Oncology, 2019, 21, vi58-vi58.	0.6	0
63	PATH-21. CLINICAL UTILITY OF DNA METHYLATION PROFILING FOR DIAGNOSIS OF CHALLENGING CENTRAL NERVOUS SYSTEM TUMORS: THE TORONTO EXPERIENCE. Neuro-Oncology, 2019, 21, vi147-vi147.	0.6	0
64	Abstract PO-060: Individualized prediction of meningioma recurrence risk over prolonged time periods. , $2021,  ,  .$		0
65	ECOA-4. Hypoxia alters the DNA methylation profile of glioblastoma tumor cells. Neuro-Oncology Advances, 2021, 3, ii1-ii2.	0.4	0
66	ECOA-8. Lung adenocarcinoma brain metastasis prediction using tumor DNA methylation profiling. Neuro-Oncology Advances, 2021, 3, ii2-ii2.	0.4	0
67	MOMC-3. Hypermethylation and overexpression of HOX genes are poor prognosticators in Lower-Grade Glioma. Neuro-Oncology Advances, 2021, 3, ii4-ii4.	0.4	0
68	Methylation profiling of EGFR mutant primary and metastatic lung cancer with brain metastasis Journal of Clinical Oncology, 2019, 37, e20574-e20574.	0.8	0
69	Abstract 4671: Novel biological roles of the atypical WNT ligand, Norrin, on glioblastoma stem cells segregate with ASCL1 expression. , 2019, , .		O
70	GCT-52. TRANSCRIPTOME OF CENTRAL NERVOUS SYSTEM GERM CELL TUMOR REVEALS ITS PATHOGENESIS AND CONTRASTS WITH TESTICULAR COUNTERPARTS IN INTEGRATED OMICS ANALYSIS. Neuro-Oncology, 2020, 22, iii338-iii339.	0.6	0
71	EPCO-01. LUNG ADENOCARCINOMA BRAIN METASTASIS PREDICTION, PREVENTION, AND NON-INVASIVE DIAGNOSIS USING METHYLATION SIGNATURES WITHIN TISSUE AND CIRCULATING TUMOUR DNA. Neuro-Oncology, 2020, 22, ii69-ii69.	0.6	0
72	BIOM-02. IDENTIFYING MGMT ALTERATIONS AS BIOMARKERS OF SURVIVAL IN LUNG ADENOCARCINOMA WITH BRAIN METASTASES. Neuro-Oncology, 2020, 22, ii1-ii1.	0.6	0

#	Article	IF	CITATIONS
73	EPCO-02. MOLECULAR CHARACTERIZATION OF TWO NOVEL MPNST SUBGROUPS IDENTIFIES THERAPEUTIC OPPORTUNITIES. Neuro-Oncology, 2020, 22, ii69-ii69.	0.6	O
74	EPCO-04. GENOMIC AND EPIGENOMIC HALLMARKS OF SCHWANNOMATOSIS SCHWANNOMAS. Neuro-Oncology, 2020, 22, ii69-ii70.	0.6	0
75	Abstract 4671: Novel biological roles of the atypical WNT ligand, Norrin, on glioblastoma stem cells segregate with ASCL1 expression. , 2019, , .		0